Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1110 - Prospective Analysis of the Risk Factors for Cisplatin-Induced Acute Kidney Injury (517P)


18 Nov 2017


Poster lunch


Akira Tsunoda


Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676


A. Tsunoda1, H. Oda1, T. Mizuno1, Y. Yamashita1, S. Tamaru1, K. Saito1, M. Ishihara1, Y. Nishimura2, K. Nakatani3, N. Katayama1

Author affiliations

  • 1 Department Of Medical Oncology, Mie University Hospital, 514-8507 - Tsu/JP
  • 2 Hospital Department Of Intergrative Pharmacology, Mie University Hospital, 514-8507 - Tsu/JP
  • 3 Department Of Clinical Laboratory, Mie University Hospital, 514-8507 - Tsu/JP


Abstract 1110


Several studies have dealt with the risk factors for prediction of cisplatin-induced acute kidney injury (AKI), such as female, hypoalbuminemia, hypopotassemia, hypomagnesemia, complications of cardiovascular disease, diabetes mellitus, advancerd cancer, total amount of cisplatin use and the combination of paclitaxel. However, these reports were retrospectively examined and their analyses were based on several differing definitions of renal injury. Therefore, the risk factors for cisplatin-induced AKI have not yet been identified.


We conducted the pilot study to aim at screening for the risk factors that would be suitable for future prospective trial. Patients with solid tumor who had received cisplatin (≧50 mg/m2)-containing chemotherapy as the first-line treatment were eligible for the study. We investigated the occurrece of AKI and its association with the baseline characteristics and their laboratory test results during the treatment. AKI was defined as the increase of serum creatinine level>0.3 mg/dL, or × 1.5-2 at baseline, according to NCI-CTCAE v4.0. Gene polymorphisms of organic cation transporter (OCT2), which is reported to affect cisplatin-induced renal injury, were analyzed with DMET Plus.


From December 2014 through June 2016, a total of 28 patients (22 males and 6 females) were enrolled. Their baseline characteristics were as follows: the median age was 65 years (range 55 to 77), and the median pretreatment serum creatinine level was 0.73 mg/dL. Tumor types were esophageal carcinoma (21 patients), gastric carcinoma (4 patients), and others (3 patients). Of 28 enrolled patients, AKI occurred in 8 patients (28.6%) and most of all developed AKI within 11 days after the start of chemotherapy. Univariate analysis showed that the level of serum cystatine C, urine β-2 microglobulin and body surface area were significantly higher in the AKI group (p


Our study suggested that serum cystatine C, urine β-2 microglobulin and body surface area may be the risk factors related to cisplatin-induced AKI.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.